Therapeutic Monoclonal Antibodies and Fragments: Ranibizumab.
Ranibizumab is a recombinant, humanized, affinity-matured, monoclonal antibody Fab fragment against all isoforms of vascular endothelial growth factor-A, which was developed specifically for intraocular use. Ranibizumab has been extensively investigated in clinical trials on choroidal neovascularization from wet age-related macular degeneration and pathologic myopia, as well as macular edema due to diabetic retinopathy and retinal vein occlusion. Numerous randomized, controlled clinical trials have shown this medication to be effective in improving both vision as well as anatomical outcomes, and the medication has repeatedly shown to have an acceptable safety profile.
Adiel G
AG
Smith
Peter K
PK
Kaiser
D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D020256:Choroidal Neovascularization / Q000188:drug therapy*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000737:chemistry; D047728:Myopia, Degenerative / Q000188:drug therapy*; D000069579:Ranibizumab / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D057135:Wet Macular Degeneration / Q000188:drug therapy*
D020533:Angiogenesis Inhibitors; D007140:Immunoglobulin Fab Fragments; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000069579:Ranibizumab